Search - tctmd.com

Displaying 341 - 360 of 392

Sort: Relevancy | Date

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

Presentation THT 2022

How to Make the Diagnosis

Presenter: Parag Goyal

February 01, 2022

Presentation THT 2022

The Underlying Pathophysiology

Presenter: Greg Lewis

February 01, 2022

Presentation THT 2022

The Role of Genetic Testing in Heart Failure (When Should You Order It)

Presenter: W. H. Wilson Tang

February 01, 2022

Presentation THT 2022

PROTECT IV: A Transcatheter Heart Failure Therapy Trial

Presenter: Gregg Stone

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Evidence for Revascularization in HFrEF Patients

Presenter: Kathleen Kearney

February 01, 2022

Presentation THT 2022

CAD and HFrEF: Mind the Gap

Presenter: Adam DeVore

February 01, 2022

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Presentation THT 2022

AMI vs HF-Shock: They Are NOT the Same

Presenter: Navin Kapur

February 01, 2022

Presentation THT 2022

Interstitial Space Fluid / Lymphatics

Presenter: Maxim Itkin

February 01, 2022

Presentation THT 2022

DCD - Donation After Cadiac Death

Presenter: Nader Moazami

February 01, 2022

Presentation THT 2022

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Presenter: Douglas Mann

February 01, 2022

Presentation THT 2022

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Presenter: Milton Packer

February 01, 2022

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Presentation THT 2022

Secubitirl-Valsartan Across the Spectrum of EFs

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Vericiguat

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

Advertisement

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

How to Make the Diagnosis

The Underlying Pathophysiology

The Role of Genetic Testing in Heart Failure (When Should You Order It)

PROTECT IV: A Transcatheter Heart Failure Therapy Trial

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Evidence for Revascularization in HFrEF Patients

CAD and HFrEF: Mind the Gap

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

AMI vs HF-Shock: They Are NOT the Same

Interstitial Space Fluid / Lymphatics

DCD - Donation After Cadiac Death

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Secubitirl-Valsartan Across the Spectrum of EFs

Vericiguat

SGLT2 Inhibitors: What the Clinician Should Know

February 2022 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content